IN VIVO CRO MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

In Vivo CRO Market, By Type of Molecule (Small Molecules and Large Molecules), By Therapeutic Area (Oncology, Cardiology, Diabetes, Autoimmune/inflammation conditions, Infectious Diseases, CNS Conditions, and Others), By Service Type (Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024
Code : CMI7148
Pages :165
Formats :
Excel and PDF
Industry : Medical Devices

Market Concentration and Competitive Landscape

In Vivo CRO Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Globalization of Clinical Trials

With growing patient populations and disease burdens in emerging markets, drug developers are seeking to enroll more trial subjects and complete studies faster. This has led to the rapid globalization of clinical trial landscape over the past decade. Companies now conduct a significant portion of their clinical trials outside traditional hubs in the U.S. and Europe. Countries across Asia, Latin America, Eastern Europe, and Africa now contribute sizeable shares to global trials. For e.g., over 60% of trials in 2020 recruited at least one subject outside U.S. and Europe combined. This trend is mostly driven by advantages like the availability of treatment naïve patients, lower costs, and quicker site initiation in these regions. However, conducting trials internationally also poses several operational and regulatory challenges. Variations exist in local ethical and biosafety norms, documentation requirements, and standards of care. Sponsors require experienced partners to navigate these complexities smoothly across global sites.

Key Players Insights